A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or Overweight

Inclusion Criteria

• Have provided informed consent before initiation of any study-specific procedures.
• Male or female participants, non-smokers, between 18 and 65 years of age (both inclusive) at screening.
• Otherwise healthy participants with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 to \<30 kg/m2).
• Female participant is eligible to participate if she is not pregnant, breastfeeding, or planning to breastfeed, and one of the following conditions applies:

• Is a woman of nonchildbearing potential (postmenopausal [12 months of amenorrhea with follicle-stimulating hormone level consistent with a postmenopausal state [FSH≥30 mIU/mL)]; or surgically sterile [hysterectomy, bilateral salpingectomy, bilateral oophorectomy, bilateral tubal occlusion/ligation]).
• Is a WOCBP and agrees to use a highly effective contraceptive method (heterosexual abstinence as a lifestyle, or a male condom in conjunction with a second method of contraception that is one of the following: established combined estrogen and/or progesterone hormonal contraception (e.g. oral contraceptive pill), depot injection, contraceptive implant, or intra-uterine device) and refrain from donating egg starting from one month before the first dose and lasting until 6 months or 5 half lives, whichever is longer, after the last dose.

Exclusion Criteria

• Have evidence of any clinically significant active or chronic disease (with the exception of obesity or overweight).
• Have obesity traced to a medical cause, suggestive of genetic or syndromic obesity or obesity induced by other endocrinologic disorders, such as hypothyroidism, Cushing syndrome, Prader-Willi syndrome and other conditions.
• Have used prescription drugs that promote weight loss within 6 months prior to the first dose of investigational product.
• Have any prior diagnosis of diabetes mellitus (T1DM or T2DM), history of ketoacidosis, or hyperosmolar state/coma.
• Presence/history of cardiovascular disease incl. stable/unstable angina, MI, TIA, stroke, cardiac decompensation, clinically significant arrhythmias or conduction disorders.
• Have a lifetime history of suicide attempt.
• Participants who have any history of hypersensitivity or intolerance to amylin receptor agonists, related compounds, or drugs of similar mechanisms of action (MoA).
• Have known liver disease, obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or abnormal liver enzymes as defined as follows at screening.

• Total bilirubin > 1.5x upper limit of normal (ULN);
• AST > 1.5x ULN;
• ALT > 1.5x ULN.
• Have an electrocardiogram (ECG) abnormality at screening as defined as follows:

• QTcF interval > 450 ms (male) or 470 ms (female)
• PR (PQ) interval prolongation (> 200 ms)
• Intermittent second or third-degree AV block, or AV dissociation
• Right bundle branch block (RBBB), left bundle branch block (LBBB), incomplete bundle branch block (IBBB), or intraventricular conduction delay (IVCD) (defined as QRS duration >120 ms).
• Elevated resting pulse rate (>100 bpm)
• Have poorly controlled high blood pressure per Investigator's judgment during screening
• Have abnormal values in calcitonin, magnesium, parathyroid hormone (PTH), vitamin D (25-hydroxycholecalciferol), and calcitriol per Investigator discretion.
• Have a presence or history of any disorder affecting calcium metabolism and bone turnover (such as hyperparathyroidism, hypoparathyroidism or Paget´s disease) per Investigator discretion
• Has had prior treatment with antiresorptive agents for osteoporosis (bisphosphonates or denosumab)